Clinical studies recruiting near Lake Forest

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · NRG Oncology · NCT05624996 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Orange County Research Center · Amgen · NCT07037433 Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Phase N/A · Northwestern Medicine Lake Forest Hospital · PrECOG, LLC. · NCT06538038 Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · Northwestern Medicine Lake Forest Hospital · SWOG Cancer Research Network · NCT06769126 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · NRG Oncology · NCT06532279 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Northwestern Medicine Lake Forest Hospital · NRG Oncology · NCT05174169 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Northwestern Medicine Lake Forest Hospital · Alliance for Clinical Trials in Oncology · NCT06632327 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Northwestern Medicine Lake Forest Hospital · Alliance for Clinical Trials in Oncology · NCT06876714 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT04269902 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Canadian Cancer Trials Group · NCT06592924 E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · Northwestern Medicine Lake Forest Hospital · NRG Oncology · NCT06748222 Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress
Phase 2 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT06649812 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT05256225 Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent
Phase 2 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT06900595 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · National Cancer Institute (NCI) · NCT05554393 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT06498635 Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT07061964 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · Northwestern Medicine Lake Forest Hospital · NRG Oncology · NCT05327686 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Northwestern Medicine Lake Forest Hospital · NRG Oncology · NCT04852887 Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Phase N/A · Wake Forest University Health Sciences · NCT03998202 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Alliance for Clinical Trials in Oncology · NCT05677490 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT06058377 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · Northwestern Medicine Lake Forest Hospital · SWOG Cancer Research Network · NCT04511013 An Internet-based Program to Help Cancer Survivors Manage Pain
NA · Wake Forest University Health Sciences · NCT04462302 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · Northwestern Medicine Lake Forest Hospital · ECOG-ACRIN Cancer Research Group · NCT04239573 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT05987241 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · Northwestern Medicine Lake Forest Hospital · National Cancer Institute (NCI) · NCT05564377 Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Phase 3 · Northwestern Medicine Lake Forest Hospital · Children's Oncology Group · NCT06513962 Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Northwestern Medicine Lake Forest Hospital · SWOG Cancer Research Network · NCT04205968

Look up another city

Look up another condition